Fierce Biotech April 24, 2024
Endeavor BioMedicines is $132.5 million richer, courtesy of another nine-digit financing round that plows additional cash runway through 2026.
The new financing, announced Wednesday, adds momentum for CEO John Hood, Ph.D., and the team, who are working to advance a two-asset pipeline that centers on a midstage idiopathic pulmonary fibrosis (IPF) drug. On its face, Endeavor seems like the kind of company that could have made a compelling case to go public, but Hood told Fierce Biotech that he wants to add a few more crossover-type investors.
In that regard, the round was a grand success. New investors include AyurMaya, an affiliate of Matrix Capital Management, along with Fidelity, Invus, SymBiosis, Velosity Capital and Woodline Partners. Hood said Endeavor set...
Today's Sponsors
Today's Sponsor